Searchable abstracts of presentations at key conferences in endocrinology

ea0022p216 | Clinical case reports and clinical practice | ECE2010

10 years experience with somatostatin analogue (SSA) treatment in multiple endocrin neoplasia type 1 (a case report)

Krisztian Sepp , Zsuzsanna Valkusz , Ildiko Kiss , Laszlo Pavics , Janos Julesz

Multiple endocrine neoplasia (MEN-1) is a rare congenital disease with genetic background. The MEN-1 gene encodes the menin protein, which acts as a tumour suppressor. Mutation of one allele and the inactivation of the other allele of this gene lead to clonal proliferation and to the development of tumours. The clinical manifestation of MEN-1 is a combination of endocrine (most commonly parathyreoid adenomas, entero-pancreatic endocrine tumours, pituitary tumours) and non-endo...

ea0029p1523 | Pituitary Clinical | ICEECE2012

GH deficiency after treatment of medulloblastoma and thyroid cancer: is this the case for GH therapy?

Valkusz Z. , Magony S. , Sepp K. , Csajbok E. , Julesz J. , Pavics L.

The hypothalamic–pituitary unit is a particularly radiosensitive region in the central nervous system. As a consequence, hypopituitarism commonly develops after radiation treatments for sellar and parasellar neoplasms, extrasellar brain tumours. Increasing tumour-related survival rates provide an expanding population at risk of developing hypopituitarism. The severity of hypopituitarism is related to the radiation doses given while whole body irradiation regimens to a dos...